

Vittorina Zagonel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2791832/vittorina-zagonel-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203
papers

7,159
citations

40
h-index

78
g-index

210
ext. papers

8,483
ext. citations

4.8
avg, IF

5.07
L-index

#	Paper	IF	Citations
203	Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy. <i>Cancers</i> , 2022 , 14, 2568	6.6	0
202	Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14).. <i>Frontiers in Oncology</i> , 2021 , 11, 787835	5.3	2
201	Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas. <i>Frontiers in Oncology</i> , 2021 , 11, 617966	5.3	1
200	Second medical opinion in oncological setting. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 160, 103282	3.2	1
199	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021 , 26, 740-750	5.7	3
198	Is burnout affecting life satisfaction in oncologists? The moderating role of family concerns in an Italian sample. <i>Psycho-Oncology</i> , 2021 , 30, 385-391	3.9	2
197	Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154	7.5	6
196	Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study. <i>Cancers</i> , 2021 , 13,	6.6	4
195	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 107-117	21.7	98
194	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 256-262.e2	3.8	22
193	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. <i>Cancers</i> , 2020 , 13,	6.6	33
192	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 69-76.e4	3.3	6
191	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020 , 5, e000911	6	35
190	Older cancer patients and COVID-19 outbreak: Practical considerations and recommendations. <i>Cancer Medicine</i> , 2020 , 9, 9193-9204	4.8	3
189	Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , 2020 , 147, 3215-3223	7.5	7
188	Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. <i>Scientific Reports</i> , 2019 , 9, 11527	4.9	9
187	Prevalence of pain in patients with cancer aged 70 years or older: A prospective observational study. <i>Journal of Geriatric Oncology</i> , 2019 , 10, 637-642	3.6	6

186	Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. <i>European Journal of Cancer</i> , 2019 , 110, 32-41	7.5	12
185	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019 , 9, 622	5.3	17
184	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1268-1275	13.4	37
183	Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients. <i>Cancers</i> , 2019 , 11,	6.6	13
182	Immune senescence and immune activation in elderly colorectal cancer patients. <i>Aging</i> , 2019 , 11, 3864-3875	3.7	6
181	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019 , 24, 1395-1402	5.7	45
180	Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2019 , 30, 533-536	2.4	5
179	Consensus document of the Italian Association of Medical Oncology and the Italian Society of Palliative Care on early palliative care. <i>Tumori</i> , 2019 , 105, 103-112	1.7	6
178	Systematic vs. on-demand early palliative care in gastric cancer patients: a randomized clinical trial assessing patient and healthcare service outcomes. <i>Supportive Care in Cancer</i> , 2019 , 27, 2425-2434	3.9	16
177	Early 7-day supplemental parenteral nutrition improves body composition and muscle strength in hypophagic cancer patients at nutritional risk. <i>Supportive Care in Cancer</i> , 2019 , 27, 2497-2506	3.9	26
176	Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 110-119	21.7	116
175	A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma. <i>Oncologist</i> , 2019 , 24, 521-528	5.7	28
174	Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 529-536	13.4	51
173	The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 251-266	3.5	29
172	Changes in food habits in cancer patients in Italy: a survey. AIOM - SINPE - FAVO. <i>Nutrition</i> , 2018 , 55-56, 140-145	4.8	10
171	Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients. <i>Acta Oncologica</i> , 2018 , 57, 412-419	3.2	0
170	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018 , 34, 148-162.e7	24.3	77
169	and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 7859-7866	3.3	18

168	Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases. <i>Anti-Cancer Drugs</i> , 2018 , 29, 924-928	2.4	1
167	Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 111, 94-102	7	61
166	Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care). <i>Tumori</i> , 2017 , 103, 9-14	1.7	9
165	Author's reply to: Patient-centered medicine in palliative cancer care: the impossible choice between physician's responsibility and patient's preferences. <i>Tumori</i> , 2017 , 103, e22	1.7	
164	Nutritional support for cancer patients: still a neglected right?. <i>Supportive Care in Cancer</i> , 2017 , 25, 3001-3004	3.9	29
163	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1297-1308	5.4	17
162	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408	4.8	20
161	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 55575-55581	3.3	9
160	Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. <i>European Journal of Cancer</i> , 2016 , 69, 110-118	7.5	80
159	Non-clinical factors influencing pain intensity in cancer patients: Socio-cultural-economic status, awareness of disease and the relation with the oncologist. <i>European Journal of Internal Medicine</i> , 2016 , 33, e18-9	3.9	4
158	Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 1069-77	4.9	38
157	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
156	Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. <i>Future Oncology</i> , 2016 , 12, 909-19	3.6	3
155	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e161-9	3.3	9
154	Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 679-85	4.9	6
153	Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study. <i>Journal of Hepatology</i> , 2016 , 65, 280-8	13.4	72
152	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 48-55	3.3	14
151	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial 2016 ,		3

150	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS774-TPS774	2.2	16
149	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 549-549	2.2	
148	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) pts receiving a new agent (NA)-based third line treatment: Preliminary results from a multicenter Italian study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 211-211	2.2	
147	Metastatic colorectal cancer (mCRC) treatment: A high-volume, single-center, real-life experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 733-733	2.2	
146	Ethics in oncology: principles and responsibilities declared in the Italian Ragusa statement. <i>Tumori</i> , 2016 , 102, e25-e27	1.7	2
145	Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey. <i>Journal of Cancer</i> , 2016 , 7, 1968-1978	4.5	10
144	Nutritional Support in Cancer Patients: A Position Paper from the Italian Society of Medical Oncology (AIOM) and the Italian Society of Artificial Nutrition and Metabolism (SINPE). <i>Journal of Cancer</i> , 2016 , 7, 131-5	4.5	78
143	Urine 2-Hydroxyglutarate in Glioma. <i>Oncologist</i> , 2016 , 21, 1026	5.7	3
142	Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. <i>Journal of Neuro-Oncology</i> , 2016 , 128, 481-6	4.8	9
141	Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey. <i>Nutrition</i> , 2016 , 32, 1028-32	4.8	45
140	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1304-12	1	53
139	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2016 , 17, 738-746	21.7	533
138	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
137	Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. <i>European Journal of Cancer</i> , 2016 , 65, 61-8	7.5	87
136	Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma. <i>Oncologist</i> , 2015 , 20, 562-7	5.7	42
135	HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases. <i>Human Pathology</i> , 2015 , 46, 665-72	3.7	31
134	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. <i>Neuro-Oncology</i> , 2015 , 17, 708-17	1	148
133	Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015 , 125, 359-67	4.8	34

132	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 2881-91	3.6	10
131	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015 , 28, 1481-91	9.8	144
130	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. <i>Familial Cancer</i> , 2015 , 14, 309-16	3	16
129	Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 514-9	2.7	37
128	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
127	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. <i>Journal of Neuro-Oncology</i> , 2015 , 122, 189-96	4.8	40
126	Time to response (TTR) and early tumor shrinkage (ETS) in recurrent glioblastoma patients treated with bevacizumab: an exploratory analysis of the prospective randomized AVAREG (ML25739) phase II study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2047-2047	2.2	1
125	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3508-3508	2.2	23
124	A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3582-3582	2.2	1
123	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 412-412	2.2	3
122	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A Real-life study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 424-424	2.2	9
121	RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with fluorouracil (flu), leucovorin (lev), and fluoropyridine (fu).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3582-3582	2.2	8
120	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 565-565	2.2	2
119	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-657	2.2	5
118	Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients. <i>Journal of the Turkish German Gynecology Association</i> , 2015 , 16, 137-44	1.1	22
117	Are circulating tumor cells (CTCs) a feasible tool for predicting disease recurrence and survival in nonmetastatic (M0) colorectal cancer (CRC)?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 650-650	2.2	
116	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 206-206	2.2	
115	Multivariable analysis of predictors of side effects of cabazitaxel in the Italian Expanded Access Program.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 225-225	2.2	

114	Temozolomide (TMZ) and radiation therapy (RT) combination in elderly patients with glioblastoma: A multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e13003-e13003	2.2	
113	Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1609-18	59.2	663
112	Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). <i>World Journal of Surgical Oncology</i> , 2014 , 12, 46	3.4	27
111	Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. <i>Cancer Treatment Reviews</i> , 2014 , 40, 951-9	14.4	37
110	Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients. <i>Scientific Reports</i> , 2014 , 4, 6828	4.9	29
109	Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. <i>PLoS ONE</i> , 2014 , 9, e84940	3.7	28
108	An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab. <i>BioMed Research International</i> , 2014 , 2014, 698542	3	7
107	The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experience. <i>BioMed Research International</i> , 2014 , 2014, 678191	3	2
106	Treatment of malignant gliomas in elderly patients: a concise overview of the literature. <i>BioMed Research International</i> , 2014 , 2014, 734281	3	13
105	Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results. <i>Chemotherapy</i> , 2014 , 60, 294-9	3.2	14
104	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , 2014 , 46, 182-6	3.3	34
103	Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3524-3524	2.2	5
102	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3664-TPS3664	2.2	1
101	Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with IDH-mutated glioma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2037-2037	2.2	
100	Activity, efficacy, and safety of nab-paclitaxel (Nab-P) and gemcitabine (G) in heavily pretreated advanced pancreatic cancer (APDAC) patients (pts): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15255-e15255	2.2	
99	Aromatase inhibitors in elderly patients with advanced breast cancer: An exploratory pharmacogenetic study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11058-11058	2.2	
98	BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 476-476	2.2	
97	Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 374-374	2.2	

96	The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. <i>Translational Oncology</i> , 2013 , 6, 10-6	4.9	38
95	Immune senescence and cancer in elderly patients: results from an exploratory study. <i>Experimental Gerontology</i> , 2013 , 48, 1436-42	4.5	31
94	Gender medicine: a task for the third millennium. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013 , 51, 713-27	5.9	101
93	Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥70 years). <i>Journal of Geriatric Oncology</i> , 2013 , 4, 340-5	3.6	14
92	The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. <i>Human Pathology</i> , 2013 , 44, 1804-10	3.7	43
91	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 549-57	1.9	38
90	Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. <i>Chemotherapy</i> , 2013 , 59, 176-80	3.2	13
89	Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature. <i>Anti-Cancer Drugs</i> , 2013 , 24, 90-7 ² .4		27
88	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3648-TPS3648	2.2	7
87	FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCR): Results of the phase III randomized TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 336-336	2.2	20
86	Retrospective analysis of sorafenib as first- or second-line targeted therapy in patients with mRCC: Three-year Italian experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 415-415	2.2	
85	Bevacizumab as front-line treatment of brain metastases from solid tumors: a case series. <i>Anticancer Research</i> , 2013 , 33, 4061-5	2.3	11
84	The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. <i>Tumori</i> , 2013 , 99, 122-4	1.7	
83	PET/CT imaging in gynecologic malignancies: a critical overview of its clinical impact and our retrospective single center analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 84-98	7	8
82	A new informed consent form model for cancer patients: preliminary results of a prospective study by the Italian Association of Medical Oncology (AIOM). <i>Patient Education and Counseling</i> , 2012 , 87, 243-9 ³ .1		12
81	Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32	6.4	32
80	Hepatoid adenocarcinoma of the colon: what should we target?. <i>Pathology and Oncology Research</i> , 2012 , 18, 93-6	2.6	20
79	Intrpleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 781-7	3.5	13

78	Early HER2 dysregulation in gastric and oesophageal carcinogenesis. <i>Histopathology</i> , 2012 , 61, 769-76	7.3	55
77	The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). <i>Annals of Surgical Oncology</i> , 2012 , 19, 3737-44	3.1	29
76	Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. <i>Human Pathology</i> , 2012 , 43, 1839-44	3.7	6
75	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 38-48	7	23
74	Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. <i>American Journal of Clinical Pathology</i> , 2012 , 137, 727-32	1.9	19
73	Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature. <i>Anti-Cancer Drugs</i> , 2012 , 23, 749-53	2.4	2
72	Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group. <i>Clinical Journal of Pain</i> , 2011 , 27, 9-18	3.5	71
71	Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 381-6	4.8	15
70	Expert conference on cancer pain assessment and classification--the need for international consensus: working proposals on international standards. <i>BMJ Supportive and Palliative Care</i> , 2011 , 1, 281-7	2.2	47
69	Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. <i>Oncologist</i> , 2011 , 16, 1175-88	5.7	34
68	Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. <i>Open Access Journal of Urology</i> , 2011 , 3, 69-82		2
67	Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome. <i>Anticancer Research</i> , 2010 , 30, 5213-6	2.3	5
66	The Medical Oncologist's Role in Palliative Care: AIOM's Position. <i>Tumori</i> , 2009 , 95, 652-654	1.7	9
65	A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 1021-7	3.5	8
64	"Care and self-care" "god as a mirror of the self". <i>Journal of Cancer Education</i> , 2009 , 24, 80-2	1.8	2
63	Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1. <i>Clinical Cancer Research</i> , 2008 , 14, 7292-303	12.9	9
62	A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 229-36	7	59
61	5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003 , 101, 4644-6; discussion 4645-6	2.2	75

60	The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. <i>Breast Cancer Research and Treatment</i> , 2003 , 78, 29-36	4.4	22
59	Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 26-32	9.7	219
58	Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. <i>Journal of Clinical Oncology</i> , 2002 , 20, 494-502	2.2	662
57	Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. <i>Blood</i> , 2002 , 99, 856-62	2.2	147
56	Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. <i>Blood</i> , 2002 , 100, 1972-6	2.2	84
55	A 20-year experience on malignant lymphomas in patients aged 70 and older at a single institute. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 37, 153-8	7	10
54	Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 39, 289-305	7	12
53	Prevalence of functional disability among elderly patients with cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2001 , 39, 269-73	7	48
52	North Thames Dialysis Study. <i>Lancet, The</i> , 2001 , 357, 720	4.0	
51	Importance of a comprehensive geriatric assessment in older cancer patients. <i>European Journal of Cancer</i> , 2001 , 37 Suppl 7, S229-33	7.5	13
50	In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies. <i>British Journal of Haematology</i> , 2000 , 110, 188-96	4.5	24
49	Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , 2000 , 22, 295-301	3.2	56
48	Re: Chronically depressed mood and cancer risk in older persons. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1080-1	9.7	0
47	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999 , 105, 225-240	4.5	17
46	Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. <i>Cancer</i> , 1999 , 86, 2006-2013	6.4	20
45	Burkitt's lymphoma in adults with and without human immunodeficiency virus infection. <i>Cancer</i> , 1998 , 82, 766-774	6.4	71
44	The impact of cancer on the physical function of the elderly and their utilization of health care. G.I.O. Ger (Gruppo Italiano Oncologia Geriatrica). <i>Cancer</i> , 1998 , 83, 589-91	6.4	11
43	Treatment of non-Hodgkin's lymphoma in the elderly: an update. <i>Hematological Oncology</i> , 1998 , 16, 1-13	3.3	11

42	Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. <i>American Journal of Hematology</i> , 1998 , 58, 105-9	7.1	95
41	Hodgkin's disease: a disorder of dysregulated cellular cross-talk. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1998 , 10, 309-20		18
40	Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. <i>Leukemia and Lymphoma</i> , 1998 , 29, 375-82	1.9	34
39	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. <i>Blood</i> , 1997 , 90, 776-782	2.2	198
38	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997 , 89, 3787-3794	2.2	51
37	CD30 Ligand Is Frequently Expressed in Human Hematopoietic Malignancies of Myeloid and Lymphoid Origin. <i>Blood</i> , 1997 , 89, 2048-2059	2.2	101
36	Rarity of microsatellite genomic instability in B-cell non-Hodgkin's lymphomas in hepatitis C virus-infected patients. <i>British Journal of Haematology</i> , 1997 , 97, 463-5	4.5	6
35	Reed-Sternberg Cells of Classical Hodgkin's Disease React With the Plasma Cell-Specific Monoclonal Antibody B-B4 and Express Human Syndecan-1. <i>Blood</i> , 1997 , 89, 3787-3794	2.2	1
34	Reducing chemotherapy-associated toxicity in elderly cancer patients. <i>Cancer Treatment Reviews</i> , 1996 , 22, 223-44	14.4	12
33	Validation of a multidimensional evaluation scale for use in elderly cancer patients. <i>Cancer</i> , 1996 , 77, 395-401	6.4	142
32	Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. <i>British Journal of Haematology</i> , 1996 , 94, 533-43	4.5	176
31	An update on the diagnostic relevance of CD26 antigen expression in CD30 positive anaplastic large cell lymphomas. <i>Human Pathology</i> , 1995 , 26, 1169-70	3.7	5
30	Total body irradiation and prednimustine in chronic lymphocytic leukemia and low grade non-Hodgkin's lymphomas. A 9-year experience at a single institution. <i>Cancer</i> , 1994 , 74, 978-84	6.4	17
29	Serum levels of adhesion molecules in haematopoietic tumours. <i>Trends in Immunology</i> , 1994 , 15, 339		3
28	The aged patient with lung cancer. Management recommendations. <i>Drugs and Aging</i> , 1994 , 4, 34-46	4.7	13
27	Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. <i>Anti-Cancer Drugs</i> , 1994 , 5, 379-93	2.4	17
26	Parenteral nutrition in cancer patients receiving chemotherapy: effects on toxicity and nutritional status. <i>Journal of Parenteral and Enteral Nutrition</i> , 1993 , 17, 513-8	4.2	37
25	Type 2 Epstein-Barr virus genome and latent membrane protein-1 expression in a T-cell-rich lymphoma of probable B-cell lineage. <i>American Journal of Clinical Pathology</i> , 1993 , 100, 541-9	1.9	9

24	Differential expression of cell adhesion molecules in B-zone small lymphocytic lymphoma and other well-differentiated lymphocytic disorders. <i>Cancer</i> , 1993 , 72, 894-904	6.4	29
23	CD13 Expression in B-Cell Chronic Lymphocytic Leukemia is Associated with the Pattern of Bone Marrow Infiltration. <i>Leukemia and Lymphoma</i> , 1992 , 6, 209-218	1.9	14
22	Follicular lymphoma of compartmentalized small cleaved center cells and mantle zone lymphocytes. Evidence for a common derivation. <i>American Journal of Clinical Pathology</i> , 1992 , 98, 437-48 ^{1.9}		16
21	B-zone small lymphocytic lymphoma: a morphologic, immunophenotypic, and clinical study with comparison to "well-differentiated" lymphocytic disorders. <i>Human Pathology</i> , 1992 , 23, 438-48	3.7	23
20	Expression of myeloid associated antigens in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1992 , 82, 173-5	4.5	8
19	A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991 , 14, 243-5	2.7	22
18	Common errors in conducting and reporting clinical trials in non-Hodgkin lymphomas and patients' age. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 811		4
17	Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990 , 13, 14-6	2.7	2
16	Bone marrow involvement in cutaneous T-cell lymphoma. <i>American Journal of Clinical Pathology</i> , 1990 , 94, 119-20	1.9	1
15	Head and neck cancer and ageing: a retrospective study in 438 patients. <i>Journal of Laryngology and Otology</i> , 1990 , 104, 634-40	1.8	56
14	Expression of natural killer antigens in a subset of 'non-T, non-B lymphoma/leukaemia with histiocytic features'. <i>British Journal of Haematology</i> , 1990 , 76, 444-8	4.5	17
13	Non-Hodgkin's lymphoma in the elderly. I. Pathologic features at presentation. <i>Cancer</i> , 1990 , 66, 1991-4	6.4	39
12	Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. <i>Cancer Investigation</i> , 1990 , 8, 577-82	2.1	20
11	Intermediate lymphocytic lymphoma encompassing diffuse and mantle zone pattern variants. A distinct entity among low-grade lymphomas?. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 113-21		13
10	Monocytoid B-cell lymphoma with bone marrow and peripheral blood involvement at presentation. <i>American Journal of Clinical Pathology</i> , 1989 , 92, 228-36	1.9	33
9	Cisplatin and etoposide as second-line chemotherapy in patients with small cell lung cancer. <i>Cancer Investigation</i> , 1988 , 6, 1-5	2.1	24
8	Age as a Risk Factor for Inadequate Treatment. <i>JAMA - Journal of the American Medical Association</i> , 1988 , 259, 41	27.4	5
7	Non-Hodgkin's Lymphoma in the Elderly: A Retrospective Evaluation of Toxicity Related to Aggressive vs. Conservative Treatments. <i>Tumori</i> , 1988 , 74, 433-438	1.7	3

6	Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 535-40		36
5	Practical Importance of Routine Paraffin-Embedded Bone Marrow Biopsy in Multiple Myeloma. <i>Tumori</i> , 1987 , 73, 315-319	1.7	4
4	Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma. <i>Investigational New Drugs</i> , 1987 , 5, 307-9	4.3	4
3	Non-Hodgkin's lymphoma in the elderly. A retrospective clinicopathologic study of 50 patients. <i>Cancer</i> , 1986 , 57, 2185-9	6.4	31
2	Staging and treatment with cyclophosphamide, vincristine and prednisone (CVP) in advanced cutaneous T-cell lymphomas. <i>Hematological Oncology</i> , 1986 , 4, 83-90	1.3	5
1	Phase II study of teniposide (VM-26) in multiple myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1985 , 8, 329-31	2.7	8